Acorda Gets FDA Nod for Drug Trial
TheStreet.com - USA
The company said that the objective of the study is to show that individuals treated with Fampridine-SR, a sustained-release tablet form of Fampridine, ...
See all stories on this topic

Acorda Therapeutics "sell"
newratings.com - USA
NEW YORK, May 23 (newratings.com) - Analysts at Morgan Joseph reiterate their "sell" rating on Acorda Therapeutics (ticker: ACOR). ...
See all stories on this topic

Hawthorne-based Acorda reaches FDA agreement
Business in the Burbs - White Plains,NY,USA
The goal of the study is to show that people treated with Fampridine-SR are significantly more likely to have consistent improvement in their walking ...
See all stories on this topic

Acorda Therapeutics (ACOR) Reaches Agreement with FDA on SPA for ...
StreetInsider.com (subscription) - Birmingham,MI,USA
The objective of the study is to show that individuals treated with Fampridine-SR are significantly more likely to have consistent improvements in their ...
See all stories on this topic

EUROSHARES Lower after Wall Street retreat; OMX surges on Nasdaq ...
Forbes - NY,USA
The broker said the current share price does not fully factor in the value of its Tysabri multiple sclerosis drug, which it markets in partnership with ...
See all stories on this topic

Elan working to fast-track Alzheimer's drug 'potential'
Irish Independent - Dublin,Ireland
The Dublin-based company also plans to test its multiple sclerosis (MS) drug Tysabri in treating various cancers, the meeting heard. ...
See all stories on this topic